BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 9586914)

  • 1. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
    Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
    J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
    Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
    Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
    Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
    Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
    J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.
    Le Chevalier T; Monnier A; Douillard JY; Ruffie P; Sun XS; Belli L; Ibrahim N; Bougon N; Bérille J
    Eur J Cancer; 1998 Dec; 34(13):2032-6. PubMed ID: 10070306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
    Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
    Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
    Sengeløv L; Kamby C; Lund B; Engelholm SA
    J Clin Oncol; 1998 Oct; 16(10):3392-7. PubMed ID: 9779718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
    Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
    J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
    Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
    Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
    Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
    J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.